For those worried about drug delivery to the low frequencies, there is a new surgical approach called canalostomy. Unlike Novartis' surgical approach for their drug which significantly damages the cochlea (cochleastomy), this doesn't at all as it enters through the edge of the vestibular system and apparently only causes minor, temporary damage to that system (none to the hearing system).
Seems like something that could be done without any additional trials if an otological surgeon wanted to do this off label.
Here is one paper on the procedure but there are a few.
https://www.jove.com/video/57351/canalostomy-as-surgical-approach-to-local-drug-delivery-into-inner
This type of surgery was also mentioned in one of Chen's papers for viral vectored gene delivery and what's neat is it starts from Apex to Base and can use the natural fluid movement of the cochlea (in the perilymph) for the drug to flow to the whole cochlea evenly since you are going "with the current". If the drug needs to be injected into the endolymph because it was only tested in that environment, that can be accessed from this site, too.
So low frequency sufferers with hair cell damage up to the moderately severe hearing loss range (possibly with severe too as long as you still have enough support cells) might have something they can discuss with an Otologic surgeon if they truly can't wait for FX-322 2.0 with better diffusion (for some people it is literally life or death). It definitely might be worth inquiring about for the severe sufferers.